

2nd Mediterranean Conference on the TREATMENT of MELANOMA





2nd Mediterranean Conference on the TREATMENT of MELANOMA



Scientific Directors Dr. Livio BLASI Dr.ssa Giuseppina SAVIO

The melanoma treatment landscape has changed over the years, since the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved understanding of the tumor microenvironment (TME) and tumor immune-evasion mechanisms resulted in new approaches to targeted therapies leading to improved outcomes for patients with advanced melanoma. Moreover, combinations with other therapeutic modalities such as chemotherapy, radiotherapy, electrochemotherapy and surgery have also been explored.

In addition, several drugs administration protocols including sequential or combination treatments are being investigated as well as strategies to overcome resistance and to potentiate the immune response.

Increasing evidence shows that tissue and blood-based biomarkers can predict the response to a therapy.

The latest findings in melanoma research, including insights into the tumor microenvironment and new biomarkers, improved understanding of tumor immune response and resistance, novel approaches for combination therapies and the role of neoadjuvant and adjuvant therapies, will be the focus of discussion at the "2" Mediterranean Conference on the Treatment of Melanoma".



2nd Mediterranean Conference on the TREATMENT of MELANOMA



2.00 pm Opening session and greetings from authorities

1° Session

Chairmen: C. Guzzetta | N. Scibetta | S. Amato


- 2.30 pm Surgical management in melanoma: where are we now and where are we going?
 - S. Di Lorenzo
- 3.00 pm The current role of sentinel node biopsy for directing the management of stage III disease G. Arnone | N. Quartuccio
- 3.30 pm Advances in melanoma staging and prognosis

 F. Fraggetta
- 4.00 pm Prognostic and predictive biomarkers in melanoma: which biomarkers are usuful in clinical practice?

 E. Unti
- 4.30 pm Role of radiotherapy in melanoma management **F. Alongi**
- 5.00 pm Discussion
- 5.30 pm End of the scientific session



2nd Mediterranean Conference on the TREATMENT of MELANOMA



2° Session

Chairman: L. Blasi

9.00 am Adjuvant treatment melanoma: target therapy and immunotherapy

P. Queirolo

9.30 am Updates on metastatic melanoma BRAF positive

G. Savio

10.00 am Updates on immunotherapy for metastatic melanoma

E. Bronte

10.30 am Host microbiota and response to immunotherapy

P. Marchetti

11.00 am Advances in basal / squamous cell carcinoma and merkel cell

T. Franchina

11.30 am Discussion

12.00 am Closing remarks and of meeting



2nd Mediterranean Conference on the TREATMENT of MELANOMA



SCIENTIFIC DIRECTORS

Dr. Livio Blasi | Dr.ssa Giuseppina Savio

CME CREDITS age.na.s. AGENZIA NAZIONALE PER SERVIZI SANITARI REGIONALI

ID CMF 326362

The conference has been granted 4,2 CME credits by the Italian National Commission for Continuing Medical Education for the following medical specialties: Physicians specializen in: dermatology and venereology, oncology, plastic and ricostructive surgery.

To obtain the CME certificate it is mandatory to: attend the congress days, fill out the Customer Satisfaction Form, successfully complete the online CME guiz.

CONGRESS REGISTRATION | Register online at www.bibagroup.it



PROVIDER AND ORGANIZING SECRETARIAT



Head Office: Via Emilia. 38 - 90144 Palermo Branch Office: Milano - Nuoro - Verona Pbx +39 091.527416 | Fax +39 091.527062 congressi@bibagroup.it | www.bibagroup.it

The conference has been organized thanks to the unrestricted grants of:



